{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T06:01:00Z","timestamp":1784786460491,"version":"3.55.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010780","name":"Celltrion Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s40261-022-01162-6","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:23Z","timestamp":1654250603000},"page":"477-489","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit"],"prefix":"10.1007","volume":"42","author":[{"given":"Rieke","family":"Alten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoorim","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-2432","authenticated-orcid":false,"given":"Dong-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4690-6054","authenticated-orcid":false,"given":"SangWook","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"1162_CR1","unstructured":"European Medicines Agency. Remsima: summary of opinion (post authorisation). 2019. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-remsima-x-62_en.pdf. Accessed 11 Apr 2022."},{"key":"1162_CR2","unstructured":"European Medicines Agency. Remsima: summary of opinion (post authorisation). 2020. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-remsima-ii\/82_en.pdf. Accessed 11 Apr 2022."},{"issue":"5","key":"1162_CR3","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/rheumatology\/keaa580","volume":"60","author":"R Westhovens","year":"2021","unstructured":"Westhovens R, Wiland P, Zawadzki M, et al. Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I\/III trial. Rheumatology (Oxford). 2021;60(5):2277\u201387.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"1162_CR4","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340\u201353.","journal-title":"Gastroenterology"},{"issue":"2","key":"1162_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S2468-1253(20)30392-7","volume":"6","author":"AM Verma","year":"2021","unstructured":"Verma AM, Patel A, Subramanian S, et al. From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative. Lancet Gastroenterol Hepatol. 2021;6(2):88\u20139.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"1162_CR6","unstructured":"Verma AM, Patel A. Switching from intravenous to subcutaneous infliximab biosimilar (Remsima\u00ae) in adult patients with inflammatory bowel disease: experience at an NHS trust. 2020. https:\/\/campus.bsg.org.uk\/wp-content\/uploads\/2021\/01\/Celltrion-supplement_Oct-2020-PI_digital-version1.pdf. Accessed 11 Apr 2022."},{"issue":"2","key":"1162_CR7","first-page":"118","volume":"114","author":"F Arg\u00fcelles-Arias","year":"2022","unstructured":"Arg\u00fcelles-Arias F, Fern\u00e1ndez \u00c1lvarez P, Castro Laria L, et al. Switch to infliximab subcutaneous during SARS-CoV-2 pandemic: preliminary results. Rev Esp Enferm Dig. 2022;114(2):118\u20139.","journal-title":"Rev Esp Enferm Dig"},{"issue":"4","key":"1162_CR8","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/apt.16770","volume":"55","author":"B Caron","year":"2022","unstructured":"Caron B, Fumery M, Netter P, et al. Letter: treatment with subcutaneous CT-P13 in Crohn\u2019s disease patients with intravenous infliximab failure. Aliment Pharmacol Ther. 2022;55(4):508\u20139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"1162_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5205","volume":"10","author":"X Baraliakos","year":"2022","unstructured":"Baraliakos X, Tsiami S, Vijayan S, et al. Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with psoriatic arthritis during the coronavirus 2 disease (COVID-19) pandemic: a case series. Clin Case Rep. 2022;10(1): e05205.","journal-title":"Clin Case Rep."},{"key":"1162_CR10","unstructured":"Alten R. Benefits of switching from IV to SC infliximab. Presented during the 'Management of rheumatic diseases during the COVID-19 pandemic' (Celltrion Healthcare) satellite symposium at EULAR Congress 2021. 2021. https:\/\/congress.eular.org\/myUploadData\/files\/industry_programme_and_exhibitors_booklet.pdf. Accessed 11 Apr 2022."},{"issue":"1","key":"1162_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5233","volume":"10","author":"S Vijayan","year":"2022","unstructured":"Vijayan S, Hwangbo K, Barkham N. Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID-19) pandemic: a case series. Clin Case Rep. 2022;10(1): e05233.","journal-title":"Clin Case Rep."},{"issue":"1","key":"1162_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/flgastro-2020-101760","volume":"13","author":"J McGoran","year":"2022","unstructured":"McGoran J, Wilson A, McErlain S, et al. Initiation of subcutaneous infliximab (Remsima) therapy for the treatment of inflammatory bowel disease during the COVID-19 pandemic. Frontline Gastroenterol. 2022;13(1):89.","journal-title":"Frontline Gastroenterol."},{"key":"1162_CR13","doi-asserted-by":"crossref","unstructured":"Buisson A, Nachury M, Reymond M, et al. Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study [abstract P400, presented at the 17th Congress of ECCO]. 2022. https:\/\/www.ecco-ibd.eu\/publications\/congress-abstracts\/item\/p400-evolution-of-clinical-and-pharmacological-parameters-after-switching-from-intra-venous-to-subcutaneous-infliximab-in-patients-with-inflammatory-bowel-disease-the-remswitch-study.html. Accessed 11 Apr 2022.","DOI":"10.1093\/ecco-jcc\/jjab232.527"},{"key":"1162_CR14","doi-asserted-by":"crossref","unstructured":"Chivato Mart\u00edn Falquina I, Saiz Chumillas RM, Arias Garcia L, et al. Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with inflammatory bowel disease: our experience in a tertiary hospital [abstract P617, presented at the 17th Congress of ECCO] 2022. https:\/\/www.ecco-ibd.eu\/publications\/congress-abstracts\/item\/p617-switching-from-an-intensified-regimen-of-infliximab-to-a-subcutaneous-standard-dose-in-adults-with-inflammatory-bowel-disease-our-experience-in-a-tertiary-hospital.html. Accessed 11 Apr 2022.","DOI":"10.1093\/ecco-jcc\/jjab232.743"},{"key":"1162_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac053","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Critchley L, Storey D, et al. Efficacy and safety of elective switching from intravenous to subcutaneous infliximab (CT-P13): a multi-centre cohort study. J Crohns Colitis. 2022. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac053.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"1162_CR16","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/rheumatology\/kel369","volume":"45","author":"EL Williams","year":"2006","unstructured":"Williams EL, Edwards CJ. Patient preferences in choosing anti-TNF therapies-R1. Rheumatology. 2006;45(12):1575\u20136.","journal-title":"Rheumatology"},{"issue":"5","key":"1162_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/hex.12063","volume":"18","author":"M Lhussier","year":"2015","unstructured":"Lhussier M, Eaton S, Forster N, et al. Care planning for long-term conditions: a concept mapping. Health Expect. 2015;18(5):605\u201324.","journal-title":"Health Expect"},{"issue":"3","key":"1162_CR18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1136\/flgastro-2019-101260","volume":"11","author":"R Kapasi","year":"2020","unstructured":"Kapasi R, Glatter J, Lamb CA, et al. Consensus standards of healthcare for adults and children with inflammatory bowel disease in the UK. Frontline Gastroenterol. 2020;11(3):178\u201387.","journal-title":"Frontline Gastroenterol."},{"issue":"10","key":"1162_CR19","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/annrheumdis-2021-220249","volume":"80","author":"E Nikiphorou","year":"2021","unstructured":"Nikiphorou E, Santos EJF, Marques A, et al. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. Ann Rheum Dis. 2021;80(10):1278\u201385.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1162_CR20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685\u201399.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1162_CR21","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1136\/annrheumdis-2014-206807","volume":"74","author":"HA Zangi","year":"2015","unstructured":"Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74(6):954.","journal-title":"Ann Rheum Dis"},{"key":"1162_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s10880-021-09801-4","author":"M Feeney","year":"2021","unstructured":"Feeney M, Chur-Hansen A, Mikocka-Walus A. People living with inflammatory bowel disease want multidisciplinary healthcare: a qualitative content analysis. J Clin Psychol Med Settings. 2021. https:\/\/doi.org\/10.1007\/s10880-021-09801-4.","journal-title":"J Clin Psychol Med Settings"},{"issue":"4","key":"1162_CR23","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/acr.23329","volume":"70","author":"A Kelly","year":"2018","unstructured":"Kelly A, Tymms K, Tunnicliffe DJ, et al. Patients\u2019 attitudes and experiences of disease-modifying antirheumatic drugs in rheumatoid arthritis and spondyloarthritis: a qualitative synthesis. Arthritis Care Res (Hoboken). 2018;70(4):525\u201332.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/PPA.S5835","volume":"3","author":"JL Barton","year":"2009","unstructured":"Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence. 2009;3:335\u201344.","journal-title":"Patient Prefer Adherence"},{"issue":"3","key":"1162_CR25","first-page":"154","volume":"22","author":"Y Edel","year":"2020","unstructured":"Edel Y, Sagy I, Pokroy-Shapira E, et al. A cross-sectional survey on the preference of patients with rheumatoid arthritis for route of administration of disease-modifying anti-rheumatic drugs: oral target-specific versus parenteral biologic. Isr Med Assoc J. 2020;22(3):154\u20139.","journal-title":"Isr Med Assoc J"},{"key":"1162_CR26","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40271-014-0075-y","volume":"8","author":"KL Stoner","year":"2015","unstructured":"Stoner KL, Harder H, Fallowfield LJ, et al. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient. 2015;8:145\u201353.","journal-title":"Patient"},{"key":"1162_CR27","first-page":"1079","volume":"10","author":"SC Bolge","year":"2016","unstructured":"Bolge SC, Goren A, Brown D, et al. Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making. Patient Prefer Adherence. 2016;10:1079\u201390.","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"1162_CR28","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1053\/j.gastro.2021.03.038","volume":"160","author":"V Solitano","year":"2021","unstructured":"Solitano V, Vuitton L, Peyrin-Biroulet L, et al. The evolution of biologics administration from intravenous to subcutaneous: treatments for inflammatory bowel disease go home. Gastroenterology. 2021;160(7):2244\u20137.","journal-title":"Gastroenterology"},{"issue":"2","key":"1162_CR29","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/rheumatology\/kep354","volume":"49","author":"S Scarpato","year":"2010","unstructured":"Scarpato S, Antivalle M, Favalli EG, et al. Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis: results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2010;49(2):289\u201394.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"1162_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0166607","volume":"11","author":"S De Mits","year":"2016","unstructured":"De Mits S, Lenaerts J, Vander Cruyssen B, et al. A nationwide survey on patient\u2019s versus physician\u00b4s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: the Be-Raise study. PLoS ONE. 2016;11(11): e0166607.","journal-title":"PLoS ONE"},{"key":"1162_CR31","first-page":"93","volume":"8","author":"TK Huynh","year":"2014","unstructured":"Huynh TK, Ostergaard A, Egsmose C, et al. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93\u20139.","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"1162_CR32","first-page":"71","volume":"7","author":"G Sylwestrzak","year":"2014","unstructured":"Sylwestrzak G, Liu J, Stephenson JJ, et al. Considering patient preferences when selecting anti-tumor necrosis factor therapeutic options. Am Health Drug Benefits. 2014;7(2):71\u201381.","journal-title":"Am Health Drug Benefits."},{"key":"1162_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24782","author":"D Sumpton","year":"2021","unstructured":"Sumpton D, Kelly A, Craig JC, et al. Preferences for biologic treatment in patients with psoriatic arthritis: a discrete choice experiment. Arthritis Care Res. 2021. https:\/\/doi.org\/10.1002\/acr.24782.","journal-title":"Arthritis Care Res"},{"issue":"Suppl. 2","key":"1162_CR34","first-page":"445","volume":"76","author":"P Sarzi-Puttini","year":"2017","unstructured":"Sarzi-Puttini P, Cortesi P, Sinigaglia L, et al. THU0634 Comparing preferences of patients with rheumatic diseases, of rheumatologists, nurses and pharmacists toward the treatment of rheumatic diseases with biological agents: results from the cara study. Ann Rheum Dis. 2017;76(Suppl. 2):445.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"1162_CR35","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1097\/MIB.0b013e3182a19268","volume":"19","author":"A Buisson","year":"2013","unstructured":"Buisson A, Seigne A-L, D\u2019Huart M-C, et al. The extra burden of infliximab infusions in inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(11):2464\u20137.","journal-title":"Inflamm Bowel Dis"},{"key":"1162_CR36","doi-asserted-by":"crossref","unstructured":"Asnong K, Hoefkens E, Lembrechts N, et al. PREVIEW study: factors associated with willingness to switch from intravenous to subcutaneous formulations of CT-P13 and vedolizumab in patients with inflammatory bowel disease [abstract and poster N02, presented at the 16th Congress of ECCO]. 2021. https:\/\/www.ecco-ibd.eu\/publications\/congress-abstracts\/item\/n02-preview-study-factors-associated-with-willingness-to-switch-from-intravenous-to-subcutaneous-formulations-of-ct-p13-and-vedolizumab-in-patients-with-inflammatory-bowel-disease.html. Accessed 11 Apr 2022.","DOI":"10.1093\/ecco-jcc\/jjab074.816"},{"issue":"8","key":"1162_CR37","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1002\/ibd.21888","volume":"18","author":"SR Vavricka","year":"2012","unstructured":"Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohn\u2019s disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18(8):1523\u201330.","journal-title":"Inflamm Bowel Dis"},{"key":"1162_CR38","unstructured":"Fiorino G, Bent-Ennakhil N, Varriale P, et al. Results from a large survey exploring patient preferences for treatment attributes in inflammatory bowel disease across 7 countries in Europe [abstract P0452, presented at UEG Week 2021]. 2021. https:\/\/programme.ueg.eu\/week2021\/#\/details\/presentations\/1148. Accessed 11 Apr 2022."},{"key":"1162_CR39","unstructured":"Schubert S, Picker N, Wilke T, et al. Patient preferences regarding treatment with advanced therapies in ulcerative colitis: a discrete-choice experiment [abstract P0486, presented at UEG Week 2021]. 2021. https:\/\/programme.ueg.eu\/week2021\/#\/details\/presentations\/1639. Accessed 11 Apr 2022."},{"issue":"1","key":"1162_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care. 2008;6(1):1\u201314.","journal-title":"Musculoskelet Care."},{"issue":"6","key":"1162_CR41","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s12325-021-01990-6","volume":"39","author":"S Schreiber","year":"2022","unstructured":"Schreiber S, Ben-Horin S, Alten R, et al. Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era. Adv Ther. 2022;39(6):2342\u201364.","journal-title":"Adv Ther"},{"key":"1162_CR42","unstructured":"European Medicines Agency. Remsima: summary of product characteristics. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf. Accessed 11 Apr 2022."},{"key":"1162_CR43","doi-asserted-by":"crossref","unstructured":"Ferrante M, Sabino J, Lobaton T, et al. Introduction of subcutaneous infliximab CT-P13 and vedolizumab in daily clinical practice: outstanding questions demonstrate the need for post-marketing studies [abstract and poster P280, presented at the 16th Congress of ECCO]. 2021. https:\/\/www.ecco-ibd.eu\/publications\/congress-abstracts\/item\/p280-introduction-of-subcutaneous-infliximab-ct-p13-and-vedolizumab-in-daily-clinical-practice-outstanding-questions-demonstrate-the-need-for-post-marketing-studies.html. Accessed 11 Apr 2022.","DOI":"10.1093\/ecco-jcc\/jjab076.405"},{"issue":"1","key":"1162_CR44","doi-asserted-by":"publisher","first-page":"1868078","DOI":"10.1080\/19420862.2020.1868078","volume":"13","author":"H Kim","year":"2021","unstructured":"Kim H, Alten R, Cummings F, et al. Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters. MAbs. 2021;13(1):1868078.","journal-title":"MAbs"},{"issue":"Suppl_2","key":"1162_CR45","first-page":"733","volume":"78","author":"D Yoo","year":"2019","unstructured":"Yoo D, Jaworski J, Matyska-Piekarska E, et al. FRI0128\u2005A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year results from a part 1 of phase I\/III randomized controlled trial in patients with active rheumatoid arthritis. Ann Rheum Dis. 2019;78(Suppl_2):733.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl_2","key":"1162_CR46","first-page":"315","volume":"77","author":"R Westhovens","year":"2018","unstructured":"Westhovens R, Yoo DH, Jaworski J, et al. THU0191\u2005Novel formulation of CT-P13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase I\/III randomised controlled trial. Ann Rheum Dis. 2018;77(Suppl_2):315.","journal-title":"Ann Rheum Dis"},{"key":"1162_CR47","unstructured":"European Medicines Agency. Remsima: assessment report on extension(s) of marketing authorisation. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/remsima-epar-public-assessment-report_en.pdf. Accessed 11 Apr 2022."},{"issue":"Suppl. 1","key":"1162_CR48","doi-asserted-by":"publisher","first-page":"S066","DOI":"10.1093\/ecco-jcc\/jjy222.096","volume":"13","author":"W Reinisch","year":"2019","unstructured":"Reinisch W, Jang BI, Borzan V, et al. DOP62 A novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomised controlled trial in patients with active Crohn\u2019s disease. J Crohns Colitis. 2019;13(Suppl. 1):S066\u20137.","journal-title":"J Crohns Colitis."},{"issue":"6","key":"1162_CR49","doi-asserted-by":"publisher","first-page":"S-1096","DOI":"10.1016\/S0016-5085(19)39701-X","volume":"156","author":"BD Ye","year":"2019","unstructured":"Ye BD, Jang BI, Borzan V, et al. Tu1715: a novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: 1-year result from a phase I open-label randomized controlled trial in patients with active Crohn\u2019s disease. Gastroenterology. 2019;156(6):S-1096.","journal-title":"Gastroenterology"},{"key":"1162_CR50","unstructured":"Schreiber S, D'Haens G, Cummings F, et al. Switching from intravenous to subcutaneous infliximab in patients with active inflammatory bowel disease: post-hoc analysis of pre\/post switch outcomes from a multicentre, randomised controlled pivotal trial [abstract and poster P0472, presented at UEG Week 2021]. 2021. https:\/\/programme.ueg.eu\/week2021\/#\/details\/presentations\/1351. Accessed 11 Apr 2022."},{"issue":"10","key":"1162_CR51","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/apt.16609","volume":"54","author":"J Hanzel","year":"2021","unstructured":"Hanzel J, Bukkems LH, Gecse KB, et al. Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn\u2019s disease and ulcerative colitis. Aliment Pharmacol Ther. 2021;54(10):1309\u201319.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1162_CR52","doi-asserted-by":"publisher","first-page":"P43","DOI":"10.1016\/j.clpt.2004.12.056","volume":"77","author":"YW Zhu","year":"2005","unstructured":"Zhu YW, Pendley C, Sisco D, et al. Pharmacokinetics and pharmacodynamics of infliximab, an anti-tumor necrosis factor-alpha monoclonal antibody, following single subcutaneous administrations in rheumatoid arthritis patients. Clin Pharmacol Ther. 2005;77(2):P43.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1162_CR53","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13075-021-02487-x","volume":"23","author":"B Combe","year":"2021","unstructured":"Combe B, Allanore Y, Alten R, et al. Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials. Arthritis Res Ther. 2021;23(1):119.","journal-title":"Arthritis Res Ther"},{"key":"1162_CR54","unstructured":"Yoo D-H, Westhovens R, Ben-Horin S, et al. Development of a subcutaneous formulation of CT-P13 (infliximab): maintenance subcutaneous administration may elicit lower immunogenicity compared to intravenous treatment [abstract 2514]. Arthritis Rheumatol. 2018;70(Suppl. 10). https:\/\/acrabstracts.org\/abstract\/development-of-a-subcutaneous-formulation-of-ct-p13-infliximab-maintenance-subcutaneous-administration-may-elicit-lower-immunogenicity-compared-to-intravenous-treatment\/. Accessed 21 May 2022."},{"issue":"9","key":"1162_CR55","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14341","volume":"75","author":"A Heald","year":"2021","unstructured":"Heald A, Bramham-Jones S, Davies M. Comparing cost of intravenous infusion and subcutaneous biologics in COVID-19 pandemic care pathways for rheumatoid arthritis and inflammatory bowel disease: a brief UK stakeholder survey. Int J Clin Pract. 2021;75(9): e14341.","journal-title":"Int J Clin Pract"},{"issue":"7","key":"1162_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102849","volume":"20","author":"F D'Amico","year":"2021","unstructured":"D\u2019Amico F, Solitano V, Aletaha D, et al. Biobetters in patients with immune-mediated inflammatory disorders: an international Delphi consensus. Autoimmun Rev. 2021;20(7):102849.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1162_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/14712598.2021.1963435","volume":"22","author":"C Agboton","year":"2022","unstructured":"Agboton C, Salameh J. Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe. Expert Opin Biol Ther. 2022;22(2):157\u2013237.","journal-title":"Expert Opin Biol Ther"},{"key":"1162_CR58","unstructured":"Joachim R. Subcutaneous infliximab in the U.S.: defining CT-P13 SC's competitive edge. 2021. https:\/\/www.biosimilardevelopment.com\/doc\/subcutaneous-infliximab-in-the-u-s-defining-ct-p-sc-s-competitive-edge-0001. Accessed 11 Apr 2022."},{"key":"1162_CR59","unstructured":"ClinicalTrials.gov. CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active Crohn's disease (NCT03945019). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03945019. Accessed 11 Apr 2022."},{"key":"1162_CR60","unstructured":"ClinicalTrials.gov. CT-P13 (infliximab) subcutaneous administration in patients with moderately to severely active ulcerative colitis (NCT04205643). 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04205643. Accessed 11 Apr 2022."},{"issue":"5","key":"1162_CR61","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","volume":"32","author":"B Bittner","year":"2018","unstructured":"Bittner B, Richter W, Schmidt J. Subcutaneous administration of biotherapeutics: an overview of current challenges and opportunities. BioDrugs. 2018;32(5):425\u201340.","journal-title":"BioDrugs"},{"issue":"6","key":"1162_CR62","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1007\/s12325-017-0545-4","volume":"34","author":"MF Kariburyo","year":"2017","unstructured":"Kariburyo MF, Xie L, Teeple A, et al. Predicting pre-emptive discussions of biologic treatment: results from an openness and preference survey of inflammatory bowel disease patients and their prescribers. Adv Ther. 2017;34(6):1398\u2013410.","journal-title":"Adv Ther"},{"key":"1162_CR63","first-page":"7","volume":"88","author":"AS Russell","year":"2011","unstructured":"Russell AS, Gulliver WP, Irvine EJ, et al. Quality of life in patients with immune-mediated inflammatory diseases. J Rheumatol. 2011;88:7\u201319.","journal-title":"J Rheumatol"},{"key":"1162_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108392","volume":"214","author":"J Spierings","year":"2020","unstructured":"Spierings J, Sloeserwij A, Vianen ME, et al. Health-related quality of life in patients with immune mediated inflammatory diseases: a cross-sectional, multidisciplinary study. Clin Immunol. 2020;214:108392.","journal-title":"Clin Immunol"},{"issue":"2","key":"1162_CR65","doi-asserted-by":"publisher","first-page":"128","DOI":"10.7861\/futurehosp.3-2-128","volume":"3","author":"S Eaton","year":"2016","unstructured":"Eaton S. Delivering person-centred care in long-term conditions. Future Hosp J. 2016;3(2):128\u201331.","journal-title":"Future Hosp J."},{"key":"1162_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24748","author":"D Sumpton","year":"2021","unstructured":"Sumpton D, Oliffe M, Kane B, et al. Patients\u2019 perspectives on shared decision-making about medications in psoriatic arthritis: an interview study. Arthritis Care Res (Hoboken). 2021. https:\/\/doi.org\/10.1002\/acr.24748.","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01162-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01162-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01162-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,11]],"date-time":"2022-06-11T13:24:06Z","timestamp":1654953846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01162-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":66,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01162-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"1 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article was supported by Celltrion Healthcare Co., Ltd (Incheon, Republic of Korea).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Rieke Alten has received consulting fees or honoraria, and lecture fees from Celltrion. Yoorim An, Dong-Hyeon Kim, and SangWook Yoon are employees of Celltrion Healthcare Co., Ltd. Laurent Peyrin-Biroulet reports grants received from AbbVie, Fresenius Kabi, MSD, and Takeda; consulting fees from AbbVie, Allergan, Alma, Amgen, Applied Molecular Transport, Arena, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Enterome, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Hikma, Index Pharmaceuticals, Inotrem, Janssen, Lilly, MSD, Mylan, Nestl\u00e9, Norgine, Oppilan Pharma, OSE Immunotherapeutics, Pandion Therapeutics, Pfizer, Pharmacosmos, Roche, Samsung Bioepis, Sandoz, Sterna, Sublimity Therapeutics, Takeda, Theravance, Tillotts, and Vifor; support for travel to study meetings, manuscript preparation, or other purposes from AbbVie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Gilead, Hikma, Janssen, MSD, Pfizer, Pharmacosmos, Sandoz, Takeda, Tillotts, and Vifor; payment for lectures, including service on speaker bureaus, from AbbVie, Amgen, Arena, Biogen, Celltrion, Ferring, Galapagos, Gilead, Hikma, Janssen, MSD, Pfizer, Pharmacosmos, Sandoz, Takeda, Tillotts, and Vifor; and stock\/stock options from CTMA.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors, including employees of the sponsor, provided intellectual contribution to manuscript development, reviewed and critically revised the manuscript, and approved the final draft.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}